Table of Contents
- Trial overview
- Who is being studied
- Trial phases and goals
- Main outcomes being measured
- Key studies involving Idarubicin Hydrochloride
- What these trials mean for patients
Trial overview
The trial data show that Idarubicin Hydrochloride is being studied in interventional trials, which means patients receive a planned treatment and the researchers measure the results.[1][2] Most studies focus on blood cancers, especially acute myeloid leukemia and acute lymphoblastic leukemia, but one study also includes hepatocellular carcinoma.[1][2]
The studies are authorised and include Phase 1, Phase 2, and Phase 3 trials.[1][2] Enrollment ranges from small early studies to large multicenter trials with more than 1,000 participants.[1][2]
Who is being studied
Several trials include newly diagnosed patients, meaning people who have just been found to have the disease.[4][6] Other studies focus on relapsed disease, which means the cancer returned after treatment, or refractory disease, which means the cancer did not respond well enough to treatment.[3][5]
The trial group also includes children, adolescents, adults, and older patients.[7][8] Some studies look at special subgroups, such as patients with KMT2A or NPM1 alterations, FLT3-ITD negative AML, NPM1-mutated AML, very high-risk T-cell ALL, or Philadelphia chromosome-positive or negative ALL.[1][4][6][7]
Trial phases and goals
Phase 1 studies in the data mainly focus on safety, tolerability, and dose finding.[5][6] One Phase 1 study in older patients with non-favorable AML looks for dose-limiting toxicity, maximal tolerated dose, and the recommended phase II dose.[5]
Phase 2 trials look more at whether the treatment works in a chosen patient group.[2][8] For example, one Phase 2 study in hepatocellular carcinoma measures disease control rate at 4 months, and another Phase 2 study in very high-risk T-ALL measures MRD negativity after induction treatment.[2][8]
Phase 3 trials are larger and compare treatment strategies.[3][4][7] These studies compare different chemotherapy backbones, add-on medicines, or consolidation plans to see which approach gives better outcomes for survival, relapse control, or treatment burden.[3][4][7]
Main outcomes being measured
The studies measure several key outcomes, including adverse events, which are unwanted medical problems during treatment, and dose-limiting toxicities, which are side effects that may stop dose increases.[5][6]
Many leukemia studies measure MRD negativity, meaning no measurable residual disease is found with the test used in the study.[4][7][8] Other important outcomes are event-free survival, overall survival, disease control rate, and complete response or remission-related measures.[2][3][4][7]
Some trials also use composite endpoints, which means more than one event is counted in the main result.[3][7] For example, one study counts relapse, death, toxicity, and resistance as part of the main endpoint.[3]
Key studies involving Idarubicin Hydrochloride
One Phase 1 study in newly diagnosed non-favorable AML in older patients tests Idarubicin Hydrochloride with cytarabine and sulfasalazine.[5] Its main goals are to find a safe dose, identify the maximal tolerated dose, and look for early signs of anti-leukemia activity.[5]
Another Phase 2 study in hepatocellular carcinoma on cirrhosis evaluates an Idarubicin Hydrochloride and Lipiodol emulsion and measures disease control at 4 months using mRECIST criteria, which is a standard way to judge tumor response on scans.[2]
A large Phase 3 AML trial in newly diagnosed FLT3-ITD negative disease compares quizartinib plus standard chemotherapy with placebo plus standard chemotherapy, and Idarubicin Hydrochloride is part of the chemotherapy backbone.[4] The main outcome is overall survival.[4]
In a Phase 3 trial for children and adolescents with AML, Idarubicin Hydrochloride appears in one treatment group among several strategies for de novo, relapsed, and transplant-related settings.[7] The study uses event-free survival, overall survival, and a composite endpoint depending on the group.[7]
Another Phase 2 trial in very high-risk T-lineage ALL studies daratumumab added to a national treatment program and measures MRD negativity after the first induction cycle.[8] A separate Phase 3 study in NPM1-mutated AML tests revumenib with intensive chemotherapy and measures event-free survival and MRD-negative complete remission.[9]
What these trials mean for patients
These studies show that Idarubicin Hydrochloride is being used as part of broader cancer treatment plans, not usually as a single study drug.[1][4][7] The research is trying to learn which combinations work best for specific patient groups, including people with newly diagnosed disease, high-risk disease, or disease that has come back.[3][5][8]
Because the studies use different phases and different outcome measures, they are asking different questions about treatment.[2][5][7] Some are mainly about safety and dosing, while others are about survival, remission, or control of the cancer over time.[3][4][8]
